Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$18.08 - $25.38 $3,959 - $5,558
-219 Reduced 2.45%
8,729 $202,000
Q2 2024

Aug 14, 2024

BUY
$24.35 - $44.39 $6,379 - $11,630
262 Added 3.02%
8,948 $217,000
Q1 2024

May 14, 2024

SELL
$31.23 - $42.99 $4,653 - $6,405
-149 Reduced 1.69%
8,686 $293,000
Q4 2023

Feb 13, 2024

SELL
$17.71 - $32.97 $4,533 - $8,440
-256 Reduced 2.82%
8,835 $278,000
Q3 2023

Nov 15, 2023

SELL
$25.44 - $37.35 $4,248 - $6,237
-167 Reduced 1.8%
9,091 $232,000
Q2 2023

Aug 11, 2023

BUY
$23.94 - $32.36 $21,689 - $29,318
906 Added 10.85%
9,258 $265,000
Q1 2023

May 15, 2023

BUY
$14.72 - $23.97 $126,253 - $205,590
8,577 New
8,577 $205,000
Q2 2022

Aug 15, 2022

SELL
$12.26 - $31.17 $102,395 - $260,331
-8,352 Closed
0 $0
Q1 2022

Aug 11, 2023

SELL
$17.64 - $39.57 $3,969 - $8,903
-225 Reduced 2.62%
8,352 $225,000
Q1 2022

May 20, 2022

SELL
$17.64 - $39.57 $38,437 - $86,223
-2,179 Reduced 20.69%
8,352 $225,000
Q4 2021

Feb 16, 2022

SELL
$34.2 - $47.56 $820 - $1,141
-24 Reduced 0.23%
10,531 $390,000
Q3 2021

Nov 12, 2021

SELL
$27.88 - $58.25 $34,320 - $71,705
-1,231 Reduced 10.44%
10,555 $504,000
Q2 2021

Aug 12, 2021

BUY
$25.79 - $42.11 $20,348 - $33,224
789 Added 7.17%
11,786 $399,000
Q1 2021

May 03, 2021

SELL
$38.75 - $86.92 $65,100 - $146,025
-1,680 Reduced 13.25%
10,997 $454,000
Q4 2020

Feb 12, 2021

BUY
$34.61 - $123.66 $134,805 - $481,655
3,895 Added 44.35%
12,677 $550,000
Q3 2020

Nov 09, 2020

BUY
$37.49 - $63.19 $45,887 - $77,344
1,224 Added 16.19%
8,782 $377,000
Q2 2020

Aug 10, 2020

BUY
$12.66 - $58.27 $95,684 - $440,404
7,558 New
7,558 $355,000

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $356M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.